On average, African American participants had greater reductions in central subfield thickness compared with eyes of white participants (−27.3 μm, P = .01), as did eyes with central subretinal fluid compared with eyes without this OCT feature (−22.9 μm, P = .01). Eyes with no prior panretinal photocoagulation (PRP) and less than severe nonproliferative diabetic retinopathy had an approximately 3-letter improvement in the VA (95% CI, 0.9-5.4 P = .007) and VA AUC (95% CI, 1.3-4.2 P < .001) analyses compared with eyes with prior PRP. For each 1% increase in hemoglobin A 1c levels, VA improvement was reduced by 1 letter in the VA (95% CI, −1.5 to −0.5 P < .001) and 0.5 letters (95% CI, −0.9 to −0.2 P < .001) in the VA AUC analyses. For every decade of participant age, the mean VA improvement was reduced by 2.1 letters (95% CI, −3.0 to −1.2 P < .001) in the VA and 1.9 letters (95% CI, −2.4 to −1.3 P < .001) in the VA AUC analyses. Across anti-VEGF treatment groups, each baseline factor was associated with mean improvement in VA and a reduction in central DME compared with the baseline.

Results Among 578 participants, the median age (interquartile range) was 61 (54-67) years. Main Outcomes and Measures Change in visual acuity (VA) and optical coherence tomography (OCT) central subfield thickness at 2 years and change in VA over 2 years (area under the curve ). Interventions Repeated 0.05-mL intravitreous injections of 2.0-mg aflibercept (201 eyes), 1.25-mg bevacizumab (185 eyes), or 0.3-mg ranibizumab (192 eyes) per protocol. Between August 22, 2012, and August 28, 2013, 660 participants were enrolled with central-involved DME and vision impairment (approximate Snellen equivalent, 20/32-20/320). Objective To identify the baseline factors that are associated with vision and anatomic outcomes when managing DME with anti-VEGF and determine if there are interactions between factors and the agent administered.ĭesign, Setting, and Participants This post hoc analysis of data from the Diabetic Retinopathy Clinical Research Network multicenter randomized clinical trial, Protocol T, was conducted between December 2016 and December 2017. Importance Identifying the factors that are associated with the magnitude of treatment benefits from anti–vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME) may help refine treatment expectations. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.

Ocala eye retina consultants